Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc. (ATNM)
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2020
Event: Announcement of the commencement of a proposed public offering of common stock or pre-funded warrants.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event regarding capital raising activities.
Material Changes
- Suspension of Existing Agreements: The Company suspended sales of securities under two existing agreements for the duration of the proposed public offering:
- The Lincoln Park Agreement (dated October 18, 2018, with Lincoln Park Capital Fund, LLC).
- The ATM Sales Agreement (dated December 28, 2018, with B. Riley FBR, Inc. and JonesTrading Institutional Services LLC).
- Agreement Status: Both the Lincoln Park Agreement and the ATM Sales Agreement remain in full force and effect, but no sales will occur under them until a new prospectus supplement is filed with the SEC.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to raise capital through a new public offering. Sales under existing facilities are paused to facilitate this new offering.
Risks and Contingencies: The filing explicitly states it does not constitute an offer to sell securities. Any sale is contingent upon a written prospectus meeting Section 10 requirements of the Securities Act of 1933 and compliance with state securities laws.
Investor Verification Checklist
- Verify the terms and pricing of the proposed public offering once the new prospectus supplement is filed.
- Confirm the duration of the suspension on the Lincoln Park and ATM Sales Agreements.
- Monitor subsequent filings for the finalization of the capital raise and its impact on share count and dilution.